drugset / Trial / NCT01747577

Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)

NCT01747577

Phase 4 Completed 68 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.

Timeline

Start
2012-12-04
Primary completion
2013-10-24
Completion
2013-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule Oral